A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

Anders Johnsson; Helga Hagman; Jan-Erik Frödin; Åke Berglund; N. Keldsen; Eva Fernebro; J Sundberg; R De Pont Christensen; K-L Garm Spindler; D Bergström; A Jakobsen

doi:10.1093/annonc/mdt236

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

Anders Johnsson, Helga Hagman, Jan-Erik Frödin, Åke Berglund, N. Keldsen, Eva Fernebro, J Sundberg, R De Pont Christensen, K-L Garm Spindler, D Bergström, A Jakobsen

Research output: Contribution to journal › Article › peer-review

Abstract

The main objective was to study the effect on progression-free survival (PFS) of adding erlotinib to bevacizumab as maintenance treatment following chemotherapy and bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC).

Original language	English
Pages (from-to)	2335-2341
Journal	Annals of Oncology
Volume	24
Issue number	9
DOIs	https://doi.org/10.1093/annonc/mdt236
Publication status	Published - 2013

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdt236

http://www.ncbi.nlm.nih.gov/pubmed/23788755?dopt=Abstract

1 Doctoral Thesis (compilation)

A targeted approach to maintenance of tumour response. Clinical and translational studies in metastatic colorectal cancer.
Hagman, H., 2017, Lund: Lund University: Faculty of Medicine. 127 p.
Research output: Thesis › Doctoral Thesis (compilation)

Open Access
File

Cite this

Johnsson, A., Hagman, H., Frödin, J.-E., Berglund, Å., Keldsen, N., Fernebro, E., Sundberg, J., De Pont Christensen, R., Garm Spindler, K.-L., Bergström, D., & Jakobsen, A. (2013). A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. Annals of Oncology, 24(9), 2335-2341. https://doi.org/10.1093/annonc/mdt236

@article{cbc307cdb4794a04bb4d7eb9196c2887,

title = "A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.",

abstract = "The main objective was to study the effect on progression-free survival (PFS) of adding erlotinib to bevacizumab as maintenance treatment following chemotherapy and bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC).",

author = "Anders Johnsson and Helga Hagman and Jan-Erik Fr{\"o}din and {\AA}ke Berglund and N. Keldsen and Eva Fernebro and J Sundberg and {De Pont Christensen}, R and {Garm Spindler}, K-L and D Bergstr{\"o}m and A Jakobsen",

year = "2013",

doi = "10.1093/annonc/mdt236",

language = "English",

volume = "24",

pages = "2335--2341",

journal = "Annals of Oncology",

issn = "1569-8041",

publisher = "Oxford University Press",

number = "9",

}

Johnsson, A , Hagman, H, Frödin, J-E, Berglund, Å, Keldsen, N, Fernebro, E, Sundberg, J, De Pont Christensen, R, Garm Spindler, K-L, Bergström, D & Jakobsen, A 2013, 'A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.', Annals of Oncology, vol. 24, no. 9, pp. 2335-2341. https://doi.org/10.1093/annonc/mdt236

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. / Johnsson, Anders ; Hagman, Helga; Frödin, Jan-Erik et al.
In: Annals of Oncology, Vol. 24, No. 9, 2013, p. 2335-2341.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

AU - Johnsson, Anders

AU - Hagman, Helga

AU - Frödin, Jan-Erik

AU - Berglund, Åke

AU - Keldsen, N.

AU - Fernebro, Eva

AU - Sundberg, J

AU - De Pont Christensen, R

AU - Garm Spindler, K-L

AU - Bergström, D

AU - Jakobsen, A

PY - 2013

Y1 - 2013

N2 - The main objective was to study the effect on progression-free survival (PFS) of adding erlotinib to bevacizumab as maintenance treatment following chemotherapy and bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC).

AB - The main objective was to study the effect on progression-free survival (PFS) of adding erlotinib to bevacizumab as maintenance treatment following chemotherapy and bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC).

U2 - 10.1093/annonc/mdt236

DO - 10.1093/annonc/mdt236

M3 - Article

SN - 1569-8041

VL - 24

SP - 2335

EP - 2341

JO - Annals of Oncology

JF - Annals of Oncology

IS - 9

ER -

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Research output

A targeted approach to maintenance of tumour response. Clinical and translational studies in metastatic colorectal cancer.

Cite this